A5070199032- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Olfactory and Sensory Function Studies
- Neurobiology of Language and Bilingualism
- Dementia and Cognitive Impairment Research
- Sleep and Wakefulness Research
- Restless Legs Syndrome Research
- Ginkgo biloba and Cashew Applications
- Constraint Satisfaction and Optimization
- Neurological diseases and metabolism
- Attention Deficit Hyperactivity Disorder
- Nuclear Receptors and Signaling
- Botulinum Toxin and Related Neurological Disorders
University of Iowa
2022-2025
Abstract Background Cognitive impairment is common at all stages of Parkinson's disease (PD), but there no consensus on which neuropsychological tests to use or how interpret cognitive battery results. A summary score (CSS) combines the richness a with simplicity single score. Objective The objective this study was determine whether CSS created using robust norming can detect early deficits in de novo, untreated PD. Methods Baseline data from PD participants and healthy control (HCs)...
We examined 2-year longitudinal change in clinical features and biomarkers LRRK2 non-manifesting carriers (NMCs) versus healthy controls (HCs) enrolled the Parkinson's Progression Markers Initiative (PPMI). analyzed data from 176 G2019S NMCs 185 HCs. All participants were assessed annually with comprehensive motor non-motor scales, dopamine transporter (DAT) imaging, biofluid biomarkers. The latter included cerebrospinal fluid (CSF) Abeta, total tau phospho-tau; serum urate neurofilament...
Abstract Importance Identifying individuals in the earliest stages of synucleinopathy is essential to evaluate drugs aimed slow progression or prevent manifest disease. Remote identification hyposmic may enable scalable recruitment participants with underlying alpha-synuclein pathology. Objective To performance a staged screening paradigm using smell testing enrich for deficit on dopaminergic transporter (DAT) imaging and pathologic aggregation. Design Cross-sectional analysis data from...
Background and Objectives The University of Pennsylvania Smell Identification Test (UPSIT) is a widely employed objective measure smell function. A revised version this test, termed the UPSIT-R, was developed in 2020 to update certain odorants response options. goal study establish normative age- sex-specific data for UPSIT-R large adult cohort compare resultant percentiles those original UPSIT. second performed relative performance these two tests small persons with without Parkinson's...
Summary Background Recent research demonstrates that α-synuclein seed amplification assays (αSyn-SAA) accurately differentiate Parkinson’s disease (PD) patients from healthy controls (HC). We used the well-characterized, multicenter Progression Markers Initiative (PPMI) cohort to further assess diagnostic performance of αSyn-SAA and examine whether assay identifies heterogeneity among enables early identification in at-risk groups. Methods analysis cerebrospinal fluid (CSF) was performed...
ABSTRACT Background and Objectives Cognitive impairment is common at all stages in Parkinson’s disease (PD). However, the field hampered by consensus over which neuropsychological tests to use how utilize results generated a cognitive battery. An option that combines richness of battery with simplicity single test score summary (CSS). The objective was determine if CSS created using robust norming sensitive detecting early deficits de novo , untreated PD. Methods Using baseline data from PD...
ABSTRACT Background REM sleep behavior disorder (RBD) is an early manifestation of alpha-synucleinopathy in many cases. Dream enactment (DEB), the clinical hallmark RBD, has etiologies and cannot be used alone to predict underlying alpha-synucleinopathy. We compared proportion people with alpha-synucleinopathy, as measured by CSF alpha-synuclein seed amplification assay (CSFasynSAA), between polysomnographic-confirmed RBD (RBD-PSG) who reported DEB on a questionnaire were further selected...
ABSTRACT Objectives To determine the impact of dopamine deficiency and isolated REM sleep behavior disorder (iRBD) on cognitive performance in early neuronal alpha-synuclein disease (NSD) with hyposmia. Methods Using Parkinson’s Progression Markers Initiative baseline data, was assessed a summary score (CSS) developed by applying regression-based internal norms derived from robust healthy control (HC) group. Performance examined for participants hyposmia classified as NSD-Integrated Staging...
Remote identification of individuals with severe hyposmia may enable scalable recruitment participants underlying alpha-synuclein aggregation. We evaluated the performance a staged screening paradigm using remote smell testing to enrich for abnormal dopamine transporter single-photon emission computed tomography imaging (DAT-SPECT) and
Background: Recent research demonstrates that α-synuclein seed amplification assays (αSyn-SAA) accurately differentiate Parkinson's disease (PD) patients from healthy controls (HC). We used the well-characterized, multicenter Parkinson’s Progression Markers Initiative (PPMI) cohort to further assess diagnostic performance of αSyn-SAA and examine whether assay identifies heterogeneity among enables early identification in at-risk groups.Methods: analysis cerebrospinal fluid (CSF) was...